Lipoprotein(a)—clinical aspects and future challenges;Lipoprotein(a) – klinische Aspekte und zukünftige Herausforderungen

Clinical Research in Cardiology Supplements

Volumn 10, Issue 1, 2015, Pages 26-32

  Kurt, Bilgen ^a   Soufi, Muhidien ^a   Sattler, Alexander ^a   Schaefer, Juergen R ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Coronary vascular disease; Lipid lowering therapy; Lipoprotein(a); Lp(a); Prevention

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; BEZAFIBRATE; CARNITINE; EVOLOCUMAB; FIBRIC ACID DERIVATIVE; HORMONE; LIPOPROTEIN A; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; NICOTINIC ACID; PLASMINOGEN; PLASMINOGEN ACTIVATOR; ROSUVASTATIN; SIMVASTATIN; STATIN (PROTEIN); VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT;

APHERESIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; ENZYME KINETICS; HEREDITY; HUMAN; INTERVENTION STUDY; KIDNEY DISEASE; LIPID ANALYSIS; LIPID DEGRADATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; BLOOD; COMPLICATION; FORECASTING; HYPERLIPOPROTEINEMIAS; PATIENT SELECTION; TREATMENT OUTCOME;

ATHEROSCLEROSIS; FORECASTING; HUMANS; HYPERLIPOPROTEINEMIAS; HYPOLIPIDEMIC AGENTS; LIPOPROTEIN(A); PATIENT SELECTION; TREATMENT OUTCOME;

EID: 84924959401     PISSN: 18610706     EISSN: 18610714     Source Type: Journal    
DOI: 10.1007/s11789-015-0075-z     Document Type: Article

References (37)

1. Berg K (1963) A new serum type system in man. Acta Pathol Microbiol Scand 59:369–382
2. Ridker PM, Hennekens CH, Stampfer MJ (1993) A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 270:2195–2199
3. Ridker PM, Stampfer MJ, Hennekens CH (1995) Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 273(16):1269–1273
4. Jauhiainen M, Koskinen P, Ehnholm C et al (1991) Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 89:59–67
5. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K, Levy RI (1994) Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271(13):999–1003
6. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302(4):412–423. doi:10.1001/jama.2009.1063
7. Kronenberg F, Utermann G (2013) Lipoprotein(a): resurrected by genetics. J Intern Med 273:6–30
8. Clarke R, Peden JF, Hopewell JC et al (2009) Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361:2518–2528
9. Schunkert H, Konig IR, Kathiresan S et al (2011) Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 43:333–338
10. Steyrer E, Durovic S, Frank S, Giessauf W, Burger A, Dieplinger H, Zechner R, Kostner GM (1994) The role of lecithin: cholesterol acyltransferase for lipoprotein (a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma. J Clin Invest 94(6):2330–2340
11. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM (1987) cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330(6144):132–137
12. Loscalzo J, Weinfeld M, Fless GM, Scanu AM (1990) Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 10(2):240–245
13. McConnell JP, Guadagno PA, Dayspring TD, Hoefner DM, Thiselton DL, Warnick GR, Harris WS (2014) Lipoprotein(a) mass: a massively misunderstood metric. J Clin Lipidol 8(6):550–553. doi:10.1016/j.jacl.2014.08.003. Epub 19 Aug 2014
14. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31:2844–2853
15. Kostner KM, März W, Kostner GM (2013) When should we measure lipoprotein (a)? Eur Heart J 34(42):3268–3276. doi:10.1093/eurheartj/eht053. Epub 4 Jun 2013
16. Krempler F, Kostner GM, Bolzano K (1980) Turnover of lipoprotein (a) in man. J Clin Invest 65:1483–1490
17. Kronenberg F, Ikewaki K, Schaefer JR, Konig P, Dieplinger H. (2007) Kinetic studies of atherogenic lipoproteins in hemodialysis patients: do they tell us more about their pathology? Semin Dial 20:554–560
18. Hoover-Plow J, Huang M (2013) Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism 62(4):479–491. doi:10.1016/j.metabol.2012.07.024
19. Schweer H, Watzer B, Seyberth HW, Steinmetz A, Schaefer JR (1996) Determination of isotopic ratios of L-leucine and L-phenylalanine and their stable isotope labeled analogues in biological samples by gas chromatography/triple-stage quadrupole mass spectrometry. J Mass Spectrom 31(7):727–734
20. Frischmann ME, Ikewaki K, Trenkwalder E, Lamina C, Dieplinger B, Soufi M, Schweer H, Schaefer JR, König P, Kronenberg F, Dieplinger H (2012) In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a). Atherosclerosis 225(2):322–327. doi:10.1016/j.atherosclerosis.2012.09.031. Epub 5 Oct 2012
21. Kostner KM, Clodi M, Bodlaj G et al (1998) Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function. Eur J Clin Invest 28:447–452
22. Frischmann ME, Kronenberg F, Trenkwalder E et al (2007) In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 71:1036–1043
23. Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, Parhofer K, Ramlow W, Koch M, Utermann G, Labarrere CA, Seidel D, Group of Clinical Investigators (2009) Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6(3):229–239. doi:10.1038/ncpcardio1456
24. Leebmann J, Roeseler E, Julius U et al (2013) Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 128:2567–2576
25. Kostner KM, Kostner GM (2004) Factors affecting plasma lipoprotein(a) levels: role of hormones and other nongenetic factors. Semin Vasc Med 4:211–214
26. Khera AV, Everett BM, Caulfield MP et al (2014) Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation 129:635–642
27. Desai NR, Kohli P, Giugliano RP, O'Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS (2013) AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation 128(9):962–969. doi:10.1161/CIRCULATIONAHA.113.001969. Epub 24 Jul 2013
28. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA (2014) Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 63(13):1278–1288. doi:10.1016/j.jacc.2014.01.006. Epub 5 Feb 2014
29. Hoover-Plow J, Huang M (2013) Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism 62(4): 479–491. doi:10.1016/j.metabol.2012.07.024
30. Roubtsova A, Munkonda MN, Awan Z, Marcinkiewicz J, Chamberland A, Lazure C, Cianflone K, Seidah NG, Prat A (2011) Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 31(4):785–791. doi:10.1161/ATVBAHA.110.220988. Epub 27 Jan 2011
31. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ (2013) Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128(19):2113–2120. doi:10.1161/CIRCULATIONAHA.113.004678. Epub 6 Sept 2013
32. Cuchel M, Meagher EA, du Toit Theron H et al (2013) Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381:40–46
33. Raal FJ, Santos RD, Blom DJ, et al. (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375:998–1006
34. Merki E, Graham M, Taleb A, Leibundgut G, Yang X, Miller ER, Fu W, Mullick AE, Lee R, Willeit P, Crooke RM, Witztum JL, Tsimikas S (2011) Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol 57(15):1611–1621. doi:10.1016/j.jacc.2010.10.052
35. Lamon-Fava S, Diffenderfer MR, Marcovina SM (2014) Lipoprotein(a) metabolism. Curr Opin Lipidol 25:189–193
36. Albers JJ, Slee A, O’Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SM (2013) Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 62(17):1575–1579. doi:10.1016/j.jacc.2013.06.051. Epub 21 Aug 2013
37. Chasman DI, Shiffman D, Zee RY, Louie JZ, Luke MM, Rowland CM, Catanese JJ, Buring JE, Devlin JJ, Ridker PM (2009) Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 203(2):371–376. doi:10.1016/j.atherosclerosis.2008.07.019. Epub 26 Jul 2008